38

Objective. To compare the role and perception of hospital pharmacists in the dispensing of oral cancer drugs in Europe and North America. Method. A descriptive, exploratory, and cross-sectional study. Identification of a hospital pharmacist by targeted legal entity. Forty-four variables were identified and grouped into three themes: demographics (n = 3), perceptions of current practice (n = 31), and perceptions of the assignment of nine pharmaceutical tasks (n = 10), as well as an optimal scenario of care. A questionnaire in English and French on SurveyMonkey® (Palo Alto, CA, USA), tested by five hospital pharmacists, was sent to participants by email. Results. Fourteen respondents (14/21, 67 %) provided usable answers (7 in Europe: Germany, Austria, Belgium, Spain, France, the Netherlands, and Switzerland; and 7 in North America: Quebec, Alberta, New Brunswick, Ontario, Manitoba, Prince Edward Island, and the United States). The validation of oral cancer drug prescription compliance involved the hospital pharmacist in 12 cases out of 14. The majority of the respondents (11/14) did not have enough resources to ensure quality supervision of all patients treated using oral cancer drugs. Conclusion. Regardless of the legal entity, most respondents considered workload to be on the rise and resources to be insufficient for ensuring quality pharmaceutical services and care (i.e., safety and proper use). This exploratory study shows the benefit of reflecting on the current model of pharmaceutical practice (hospital versus pharmacy) in order to ensure adequate and efficient treatment for cancer patients.